Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

α4Integrins as Therapeutic Targets in Autoimmune Disease

von Andrian, Ulrich H., Engelhardt, Britta·2003·New England Journal of Medicine

Abstract

In this issue of the Journal, two groups of investigators report on clinical trials of natalizumab, a recombinant monoclonal antibody against α4 integrins, for the treatment of multiple sclerosis1 and Crohn's disease.2 Miller et al. report that a group of patients with multiple sclerosis who received monthly injections of natalizumab had significantly fewer new inflammatory central nervous system lesions than the placebo group (a reduction of approximately 90 percent) and had approximately half as many clinical relapses.1 Ghosh et al. report that patients with Crohn's disease also had an improved response to natalizumab,2 with response and remission rates that . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejme020157

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 276

Metadata

Authors
von Andrian, U. H., & Engelhardt, B.
Venue
New England Journal of Medicine
Published
2003-01-02
Volume
348
Issue
1
Pages
68-72
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1982947309
Cited by
276
References
17
FWCI
14.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: α4Integrins as Therapeutic Targets in Autoimmune Disease. https://app.cochat.ai/papers/10.1056/nejme020157
The paper
von Andrian, U. H., & Engelhardt, B. (2003). α4Integrins as Therapeutic Targets in Autoimmune Disease. New England Journal of Medicine. https://doi.org/10.1056/nejme020157

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.